Judit Jørgensen

1.2k total citations
60 papers, 691 citations indexed

About

Judit Jørgensen is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Judit Jørgensen has authored 60 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pathology and Forensic Medicine, 31 papers in Oncology and 18 papers in Neurology. Recurrent topics in Judit Jørgensen's work include Lymphoma Diagnosis and Treatment (48 papers), CNS Lymphoma Diagnosis and Treatment (18 papers) and CAR-T cell therapy research (13 papers). Judit Jørgensen is often cited by papers focused on Lymphoma Diagnosis and Treatment (48 papers), CNS Lymphoma Diagnosis and Treatment (18 papers) and CAR-T cell therapy research (13 papers). Judit Jørgensen collaborates with scholars based in Denmark, Sweden and Finland. Judit Jørgensen's co-authors include Peter de Nully Brown, Sirpa Leppä, Harald Holte, Tarec Christoffer El‐Galaly, Francesco d’Amore, Marja‐Liisa Karjalainen‐Lindsberg, Matias Autio, Pär Josefsson, Suvi‐Katri Leivonen and Thomas Stauffer Larsen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Judit Jørgensen

54 papers receiving 686 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judit Jørgensen Denmark 15 469 343 136 124 103 60 691
Daniel Martı́nez Spain 17 384 0.8× 299 0.9× 166 1.2× 280 2.3× 108 1.0× 60 814
Sarah M. Larson United States 14 201 0.4× 343 1.0× 180 1.3× 200 1.6× 77 0.7× 74 749
Geoffrey Chong Australia 15 307 0.7× 393 1.1× 151 1.1× 179 1.4× 62 0.6× 59 769
Reem Karmali United States 17 647 1.4× 559 1.6× 137 1.0× 192 1.5× 160 1.6× 116 1.0k
Naoko Tsuyama Japan 13 380 0.8× 331 1.0× 73 0.5× 117 0.9× 108 1.0× 44 605
Hervé Tilly France 14 696 1.5× 327 1.0× 58 0.4× 132 1.1× 78 0.8× 27 856
Viola Poeschel Germany 13 707 1.5× 459 1.3× 61 0.4× 269 2.2× 79 0.8× 39 872
F. Morschhauser France 13 693 1.5× 449 1.3× 117 0.9× 182 1.5× 168 1.6× 27 944
C Gisselbrecht France 15 543 1.2× 451 1.3× 152 1.1× 181 1.5× 177 1.7× 36 860
Allison Crosby‐Thompson United States 6 675 1.4× 393 1.1× 58 0.4× 181 1.5× 146 1.4× 11 891

Countries citing papers authored by Judit Jørgensen

Since Specialization
Citations

This map shows the geographic impact of Judit Jørgensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judit Jørgensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judit Jørgensen more than expected).

Fields of papers citing papers by Judit Jørgensen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judit Jørgensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judit Jørgensen. The network helps show where Judit Jørgensen may publish in the future.

Co-authorship network of co-authors of Judit Jørgensen

This figure shows the co-authorship network connecting the top 25 collaborators of Judit Jørgensen. A scholar is included among the top collaborators of Judit Jørgensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judit Jørgensen. Judit Jørgensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.
2.
3.
Jensen, Paw, Peter de Nully Brown, Pär Josefsson, et al.. (2025). Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal Of Haematology. 114(5). 832–839.
4.
Jakobsen, Lasse, Sandra Eloranta, Karin E. Smedby, et al.. (2024). Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study. European Journal Of Haematology. 113(5). 641–650. 2 indexed citations
5.
Michot, Jean‐Marie, Franck Morschhauser, Silvia Martina Ferrari, et al.. (2024). Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 144(Supplement 1). 869–869. 1 indexed citations
6.
Bæch, Joachim, Lasse Hjort Jakobsen, Marianne Tang Severinsen, et al.. (2024). Survival outcomes and healthcare utilization between immigrant patients and Danish-born patients with hematological cancers: a Danish population-based study. European Journal of Epidemiology. 39(8). 881–892. 1 indexed citations
7.
Brown, Peter de Nully, Matthew J. Maurer, Arushi Khurana, et al.. (2024). The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study. Leukemia & lymphoma. 65(14). 2173–2181. 2 indexed citations
8.
Pedersen, Lars, Jonas Jensen, Peter de Nully Brown, et al.. (2024). The long‐term risk of immune‐related conditions in survivors of diffuse large B‐cell lymphoma: A Danish nationwide registry study. SHILAP Revista de lepidopterología. 6(1). e1070–e1070. 1 indexed citations
9.
Bæch, Joachim, Simon Husby, Kristian Kragholm, et al.. (2023). Cardiovascular diseases after high‐dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population‐based study. British Journal of Haematology. 204(3). 967–975. 3 indexed citations
10.
Jakobsen, Lasse Hjort, Kristian Kragholm, Joachim Bæch, et al.. (2023). Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study. Clinical Epidemiology. Volume 15. 337–348. 4 indexed citations
11.
Leppä, Sirpa, Leo Meriranta, Martti Arffman, et al.. (2023). BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CELL LYMPHOMA (NLG‐LBC‐06 PHASE II TRIAL): IMPACT OF CTDNA AND TP53 ABERRATIONS ON CLINICAL OUTCOME. Hematological Oncology. 41(S2). 51–52. 1 indexed citations
12.
Jakobsen, Lasse Hjort, Boris Modrau, Kristian Kragholm, et al.. (2023). Risk of dementia among older patients with lymphoma: A Danish nationwide matched cohort study. Journal of Geriatric Oncology. 15(1). 101672–101672. 2 indexed citations
13.
14.
Bæch, Joachim, Marianne Tang Severinsen, Henrik Frederiksen, et al.. (2022). Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy. Blood Advances. 6(15). 4427–4435. 2 indexed citations
15.
Leivonen, Suvi‐Katri, et al.. (2022). Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma. SHILAP Revista de lepidopterología. 3(3). 681–687. 4 indexed citations
16.
Jakobsen, Lasse Hjort, Marianne Tang Severinsen, Joachim Bæch, et al.. (2022). Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer Journal. 12(1). 16–16. 6 indexed citations
17.
Leivonen, Suvi‐Katri, Maja Ludvigsen, Harald Holte, et al.. (2021). Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. Cancers. 13(3). 398–398. 18 indexed citations
18.
Meriranta, Leo, Amjad Alkodsi, Annika Pasanen, et al.. (2021). Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 139(12). 1863–1877. 71 indexed citations
19.
20.
Jørgensen, Judit, Flemming Brandt Sørensen, Knud Bendix, et al.. (2007). Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes. Leukemia & lymphoma. 48(3). 584–595. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Martı́nez Breakdown of academic impact, for papers by Sarah M. Larson Breakdown of academic impact, for papers by Geoffrey Chong Breakdown of academic impact, for papers by Reem Karmali Breakdown of academic impact, for papers by Naoko Tsuyama Breakdown of academic impact, for papers by Hervé Tilly Breakdown of academic impact, for papers by Viola Poeschel Breakdown of academic impact, for papers by F. Morschhauser Breakdown of academic impact, for papers by C Gisselbrecht Breakdown of academic impact, for papers by Allison Crosby‐Thompson
Rankless by CCL
2026